All In Biotech

Drug Trial Radar · NCT04600167

Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes

Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,000

Planned (sponsor's estimate)

Start

Jun 17, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Dr. Nyanda Elias NtinginyaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands; Otago University, New Zealand; Makerere University; St George's, University of London; Kilimanjaro Christian Medical University College (KCMUCo), Tanzania; Uganda Martyrs Hospital Lubaga, Uganda; King's College London
First posted
Oct 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes globally. This may be expected to rise substantially as DM prevalence increases. Treatment of Latent TB Infection (LTBI) in this population will likely have a significant clinical benefit. Similar to HIV-infected individuals, those with DM might benefit from therapy to prevent the development of TB disease. Current international guidelines do not recommend LTBI management in people with DM, but this is because no studies have examined the risk-benefit ratio of such an intervention. To date, no RCTs have been conducted to investigate the efficacy and safety of preventive treatment of LTBI in DM patients. Based on evidence on effectiveness, safety, and treatment completion rates, 3HP has been selected as the regimen of choice for this study of African people living with DM. People living with DM will be randomized to 3HP or placebo to determine the efficacy of 3HP in the prevention of TB disease in this population. PROTID's preventive treatment of LTBI among people with DM will generate the first solid evidence to support or refute the use of preventive treatment against TB in people with DM.

Conditions

  • Diabetes Mellitus
  • Tuberculosis

Interventions

  • Isoniazid and Rifapentine (INH-RPT)Drug

    Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.

  • PlaceboDrug

    Participants in the control group will receive placebo once weekly for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First diagnosis of TBTime frame: Through study completion, median of 33 months follow-up

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Mbeya zonal referral hospital

    Mbeya, Tanzania · Recruiting

  • Kilimanjaro Christian Medical Center

    Moshi, Tanzania · Recruiting

  • Makerere University

    Kampala, Uganda · Recruiting

  • Martyrs Hospital Lubaga

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.